Ligand Pharmaceuticals (LGND) Convertible Debt (2014 - 2022)

Ligand Pharmaceuticals has disclosed Convertible Debt across 8 years of filings, most recently posting $176.5 million for Q1 2022.

• Convertible Debt for Q1 2022 came in at $176.5 million, down 49.89% year-over-year; the trailing twelve-month figure through Mar 2022 was $176.5 million (down 49.89% YoY), and the FY2021 annual result was $320.7 million, down 27.49% from the prior year.
• Convertible Debt came in at $176.5 million for Q1 2022 at Ligand Pharmaceuticals, down from $320.7 million in the prior quarter.
• In the past five years, Convertible Debt ranged from a high of $639.0 million in Q4 2019 to a low of $176.5 million in Q1 2022.
• The 5-year median for Convertible Debt is $452.3 million (2020), against an average of $474.6 million.
• Across the five-year window, Convertible Debt rose 4.77% in 2019 and sank 49.89% in 2022, its largest moves.
• Ligand Pharmaceuticals' Convertible Debt stood at $609.9 million in 2018, then grew by 4.77% to $639.0 million in 2019, then tumbled by 30.78% to $442.3 million in 2020, then declined by 27.49% to $320.7 million in 2021, then sank by 44.95% to $176.5 million in 2022.
• The last three Convertible Debt figures came in at $176.5 million (Q1 2022), $320.7 million (Q4 2021), and $316.9 million (Q3 2021), per Business Quant data.